Skip to Content

The Cigna Group

CI: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$928.00NvyksbMblxgbcr

As Cigna Posts Strong 2Q, Fair Value Unchanged

Narrow-moat Cigna turned in strong second-quarter operating results that allowed management to boost its 2022 outlook a bit. Even after incorporating these mildly stronger near-term expectations, our $299 fair value estimate has not changed materially. Shares appear to be moving closer to fair value due to the company's operational momentum.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of CI so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center